Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel or Cabazitaxel With Clarithromycin in Castrate-Resistant Prostate Cancer
NCT03043989Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clarithromycin in prostate cancer (PCa) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Treatment-related adverse events at 3 years and Maximum Tolerated Dose at 3 years. Started Mar 2017; status: terminated.
02
Drugs
clarithromycin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03043989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03043989.